Level of tumor-infiltrating lymphocytes and PD status as potential prognostic markers of survival and therapy effectiveness in triple-negative breast cancer

In breast cancer, genetic profile and expression of immunohistochemical markers determine prognosis and treatment scheme. Triple-negative breast cancer is characterized by absence of hormone receptor expression and negative HER2 status, as well as high proliferative index. These features of the tumor tissue limit doctors» selection of antitumor drugs. Development of triple-negative variant of tumor tissue is associated with a mutation in the BRCA1/2 gene. Consequently, determination of BRCA1/2 mutations is a prognostic biomarker, and in triple-negative cancer presence of expression of immune checkpoint proteins, multiprotein receptors on the surface of immune cells and tumor tissue play an important role in prognosis and selection of treatment strategy. Additionally, some studies demonstrate existence of multiple prognostic markers which allow to divide patients with triple-negative breast cancer into subgroups facilitating prognosis and selection of treatment strategy.

breast cancer, BRCA mutations, neoantigen load, tumor-infiltrating lymphocytes, tumor PD status, triple-negative phenotype

1. Nefedova N.A., Danilova N.V. Clinicopathologic characterization of the subtypes of triple negative breast cancer. Fundamentalnye issledovaniya = Fundamental Research 2013;(9–5):881–5. (In Russ.).

2. Lynce F., Xiu J., Obeid E. et al. Tumor mutational load in gynecological and breast cancer. J Clin Oncol 2017;35(Suppl 7S):abstr. 44.

3. Qin T., Zeng Y.D., Qin G. et al. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget 2015;6(32):33972–81. DOI: 10.18632/oncotarget.5583.

4. Peshkin B.N., Alabek M.L., Isaacs C. BRCA1/2 mutations and triple negative breast cancers. Breast Dis 2010;32(1– 2):25–33. DOI: 10.3233/BD-2010-0306.

5. Audeh M.W., Dadmanesh F., Yearley J. PD-L1 expression in primary breast cancers with germline mutations in BRCA1 and 2. Cancer Res 2016;76(4 Suppl):abstr. P4-04-01.

6. Strickland K.C., Howitt B.E., Shukla S.A. et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 2016;7(12):13587–98. DOI: 10.18632/oncotarget.7277.

7. Adams S., Gray R.J., Demaria S. et al. Badve prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014;32(27):2959–66. DOI: 10.1200/JCO.2013.55.0491.

8. Pruneri G., Gray K.P., Vingiani A. et al. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial. Breast Cancer Res Treat 2016;158(2):323–31. DOI: 10.1007/s10549-016-3863-3.

9. Farmer H., McCabe N., Lord C.J. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917–21. DOI: 10.1038/nature03445.

10. Robson M., Im S.-A., Senkus E. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. Engl J Med 2017;377:523–33. DOI: 10.1056/NEJMoa1706450.

11. Litton J., Rugo H.S., Ettl J. et al. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. Cancer Res 2018;78(4 Suppl):abstr. GS6-07.

12. Zishuo H.I., McArthur H.L. Immunotherapy in breast cancer: the new frontier. Curr Breast Cancer Rep 2018;10(2):35–40. DOI: 10.1007/s12609-018-0274-y.

13. Shiping J., Weiya X., Hirohito Y. et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017;23(14):3711–20. DOI: 10.1158/1078-0432.CCR-16-3215.